



Factors Influencing Background Incidence Rates: Systematic Empirical Evaluation Across an International Network of Observational Databases

Anna Ostropolets Columbia University Medical Center



Thanks to all co-authors and collaborators:

Xintong Li, Rupa Makadia, Gowtham Rao, Peter R. Rijnbeek, Talita Duarte-Salles, Martijn Schuemie, Anthony G. Sena, Azza Shaoibi, Marc A. Suchard, Patrick B. Ryan, Daniel Prieto-Alhambra and George Hripcsak



Factors Influencing Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases. Frontiers in Pharmacology; 2022



Drug (vaccine) safety studies

VS

Observed rate of adverse event

FDA's Adverse Event Reporting System Adverse events following exposure in EHR and claims data Expected rate of adverse event

Background (baseline, historic) rates of adverse events in EHR and claims data



Background incidence rates



New cases



Time at risk (TAR)

New cases during specified time period

Background incidence rate


Person-time of the at-risk population



Population



Systematic experiment



10 research questions, compute incidence rates and incidence rate ratios, random effect model meta-analysis



Magnitude of influence

| Age | | factor of 1,000 | Race | 2 |
|--|-----|------------------------------------|--|-----|
| E.g., pooled incidence rates of acute myocardial infarction in 6-17 yo is <1 per 100,000 PY and ~1,330 per 100,000 in 85+ yo group | | | Season* | 1.5 |
| Data source | 100 | | New case identification strategy | 1.5 |
| Index date (anchoring) | 50 | * Date vs visit | (clean window) | |
| Condition subgroups* | 4 | * Patients with chronic conditions | * Season and comparison of COVID-19 pandemic versus previous years | |
| Gender | 2 | | | |



Selecting an index date in a cohort or case-crossover study

Exposed group/time



Drug exposure date Vaccination date Procedure date


Unexposed group/time



January 1st?
A random date?
A visit?
Something else?



Anchoring on a visit increases incidence rates for short and medium time-at-risk intervals for all conditions



Comparison of anchoring on a random visit versus anchoring on January 1st in patients with a visit in the next year, incidence rate ratio.



Magnitude of influence

| Age | | factor of 1,000 | Race | 2 |
|--|-----|------------------------------------|--|-----|
| E.g., pooled incidence rates of acute myocardial infarction in 6-17 yo is <1 per 100,000 PY and ~1,330 per 100,000 in 85+ yo group | | | Season* | 1.5 |
| Data source | 100 | | New case identification strategy | 1.5 |
| Index date (anchoring) | 50 | * Date vs visit | (clean window) | |
| Condition subgroups* | 4 | * Patients with chronic conditions | * Season and comparison of COVID-19 pandemic versus previous years | |
| Gender | 2 | | | |



Key findings

- Age has the largest impact on incidence with incidence rates varying up to a factor of 1,000 across age groups.
- Anchoring has a great impact on incidence rates (and patient characteristics). Anchoring time-at-risk interval on any type of healthcare encounter yielded higher incidence when compared to anchoring on a random date, especially for the short time-at-risk.
- Temporal and seasonal trends, gender, race and clean window choice have moderate influence



Key implications

• As population characteristics have high impact on baseline rates, population used for background rates calculation should represent the population for observed rate calculations

• As background rates don't have a definitive point-in-time index date for time-at-risk interval, we must select an index date or event (anchor) that serves as a counterfactual for exposure (vaccination) based on the background knowledge and empirical assessment